← Back to Search
Effects Of Interleukin-2 Therapy Combined With Highly Active Antiretroviral Therapy On Immune Restoration In HIV-1 Infection: A Randomized Controlled Trial
Y. Lévy, C. Durier, R. Krzysiek, C. Rabian, C. Capitant, A. Lascaux, C. Michon, E. Oksenhendler, L. Weiss, J. Gastaut, C. Goujard, C. Rouzioux, J. Maral, J. Delfraissy, D. Émilie, J. Aboulker
Published 2003 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Background: Intermittent interleukin-2 (IL-2) therapy leads to a sustained increase of CD4 T cells in HIV-1-infected patients. Methods: Symptom-free HIV-1-infected patients who were naive to all antiretroviral drugs (n = 68) and/or to protease inhibitors (n = 50) and had a CD4 cell count of 200–550 × 106 cells/l were randomly assigned to start lamivudine/stavudine/indinavir alone (controls) or combined from week 4 with subcutaneous IL-2 (5 × 106 IU twice daily for 5 days: every 4 weeks for three cycles, then every 8 weeks for seven cycles). Immunological and virological results were monitored until week 74. Results: CD4 T cell counts increased more in the IL-2 group than in the controls (median increases 865 and 262 × 106 cells/l, respectively; P < 0.0001); an 80% increase in CD4 T cells was achieving by 89% of the IL-2 group and by 47% of the controls (P < 0.0001). Decrease of plasma viral loads was similar in both groups. Compared with controls, IL-2 induced a greater increase of naive and memory CD4 T cells, lymphocyte expression of CD28 and CD25 (P < 0.0001) and natural killer cells (P < 0.001). In a logistic regression analysis, odds of being responders to recall antigens in vitro was 8.5-fold higher in IL-2 recipients (P = 0.002) than in controls. The former experienced a higher level of antibody response to tetanus vaccination at week 64 than controls (32 and 8 haemagglutinating units/ml, respectively; P = 0.01). Conclusions: The combination of antiviral drugs and IL-2 induced a greater expansion and function of CD4 T cells than antiretroviral drugs alone.
This paper references
Interleukin-2: inception, impact, and implications.
K. Smith (1988)
Safety and Effects of Interleukin‐2 Plus Zidovudine in Asymptomatic Individuals Infected with Human Immunodeficiency Virus
D. Schwartz (1991)
A Phase I study of subcutaneous recombinant interleukin‐2 in patients with advanced HIV disease while on zidovudine
D. McMahon (1994)
How B and T cells talk to each other
E. Clark (1994)
Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.
J. Kovacs (1995)
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
J. Kovacs (1996)
Sustained increases in CD4 counts with intermittent interleukin-2 therapy in HIV-infected patients with greater than 200 CD4 cells/mm3: results of a randomized, controlled trial
JA Kovacs (1996)
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.
R. Davey (1997)
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
B. Autran (1997)
Subcutaneous administration of interleukin-2 in HIV-1 infected persons
RT Davey (1997)
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
F. Palella (1998)
Changing patterns of mortality across Europe in patients infected with HIV-1
A. Mocroft (1998)
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
S. Michaels (1998)
Randomized, controlled phase II trial of subcutaneous interleukin‐2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
U. Hengge (1998)
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.
R. Davey (1999)
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with =250/microL CD4 T cells and undetectable plasma virus load.
A. Arnó (1999)
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
A. Carr (1999)
Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
C. Simonelli (1999)
Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial
Y. Lévy (1999)
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
B. Ledergerber (1999)
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with<250/ìl CD4 T cells and undetectable plasma viral load
A Arno (1999)
for the ANRS 048 Study Group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection:a randomised controlled trial
Y Levy (1999)
ANRS 048 Study Group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection:a randomised controlled trial
Y Levy (1999)
Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus
A Carr (1999)
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with<250/ l CD4 T cells and undetectable plasma viral load
A Arno (1999)
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
R. Davey (2000)
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.
M. Burgard (2000)
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
M. Losso (2000)
Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization.
I. Fogelman (2000)
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
K. Ruxrungtham (2000)
Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens.
S. Fournier (2001)
Immune reconstitution under HAART is associated with restoration of lymphocyte proliferation and gamma-interferon production in presence of Toxoplasma gondii antigens
S Fournier (2001)
Participat - ing clinical departments : Hôpital Henri Mondor , Créteil ( Y . Levy , A . - S . Lascaux , K . Bouchenafa , C . Jung ) ; Hôpital Louis Mourier , Colombes ( C . Michon ,
J. Maral Y. Levy
This paper is referenced by
Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults
Jennifer Onwumeh (2017)
Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV
Braira Wahid (2016)
Multifarious immunotherapeutic approaches to cure HIV-1 infection
N. Imami (2015)
Lymphoma and Epstein−Barr virus DNA in blood during interleukin‐2 therapy in antiretroviral‐naïve HIV‐1‐infected patients: a substudy of the ANRS 119 trial
V. Lastours (2014)
Interleukin-2 (IL-2) is a naturally-occurring immune system signaling molecule that promotes lymphocyte generation. Intravenous recombinant IL-2, called aldesleukin, has FDA approval for use in patients with metastatic renal cell carcinoma and metastatic melanoma. Aldesleukin also is being investiga
Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease.
Louis Pérol (2014)
Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.
A. Herasimtschuk (2014)
infection treated with interleukin-2 Expansion of CD1d-restricted NKT cells in patients with primary HIV-1
Douglas F. Nixon (2013)
Immune interventions in HIV infection
G. Carcelain (2013)
Modeling interleukin-2-based immunotherapy in AIDS pathogenesis.
Marcel Joly (2013)
Promoting immunity during chronic infection--the therapeutic potential of common gamma-chain cytokines.
Jesse G. Toe (2013)
Role of Interleukin-2 in Patients with HIV Infection
S. Pett (2012)
Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV
Y. Lévy (2012)
HIV RNA Suppression and Immune Restoration: Can We Do Better?
M. Pinzone (2012)
In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.
Yelina Alvarez (2012)
IL-2 immunotherapy in chronically SIV-infected Rhesus Macaques
J. Garibal (2012)
Safety and efficacy of Setarud (IMOD TM ) among people living with HIV/AIDS: a review.
K. Paydary (2012)
Mechanisms underlying immunomodulation of HIV-1-specific T-cell responses
A. Herasimtschuk (2012)
Immune reconstitution in HIV-1 infection : the effects of antiretroviral and immune therapy
A. Sullivan (2011)
Immunotherapeutic restoration in HIV-infected individuals.
J. Kim (2011)
Despite an impaired response to IL-7, T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI
Y. Pacheco (2011)
Thoughts on Intervention in HIV/AIDS with Traditional Chinese Medicine
Xin-fang Wu (2011)
Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis.
J. van Grevenynghe (2011)
Impact of γ‐chain cytokines on T cell homeostasis in HIV‐1 infection: therapeutic implications
M.-L. Gougeon (2010)
Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients
F. Sabbatini (2010)
IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the Periphery
L. Ndhlovu (2010)
Modulation of invariant NKT cell activity by cytokines and receptors in human disease
Carlotta Kuylenstierna (2010)
In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2–treated HIV patients
L. Weiss (2010)
IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.
E. Fontas (2010)
Title IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD 4 + T ( TH 17 ) Cells in the Periphery Permalink
L. Ndhlovu (2010)
Interleukin-2 therapy in patients with HIV infection.
D. Abrams (2009)
The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.
L. Gazzola (2009)See more